Speech-Language Pathologists in Poplar Grove, IL Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Ashley Lynn Moritz, M.S., CCC-SLP/L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4950 Route 173, Poplar Grove, IL 61065 Phone: 815-765-2113    Fax: 815-765-0003

Mr. Jeffry Stephen Clow, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 492 Prairie Knoll Dr, Poplar Grove, IL 61065 Phone: 815-544-0854

Lauren Licausi, M.S., CCC-SLP/L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6248 N Boone School Rd, Poplar Grove, IL 61065 Phone: 815-765-3322

Maegan O'brien, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1237 Candlewick Dr Nw, Poplar Grove, IL 61065 Phone: 630-450-2622

Dr. Laura Grant, PHD, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3501 Blaine Rd, Poplar Grove, IL 61065 Phone: 815-765-9436    Fax: 815-765-9436

Kelly Zane Maffei, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4950 Route 173, Poplar Grove, IL 61065 Phone: 815-765-2113

News Archive

Biophysicists visualize atomic-level dynamics of largest protein-degrading machine

Protein dynamics are essential for their functions. Protein nanomachines made of multiple protein molecules are highly dynamics during their actions on their functional targets, sometime called substrates.

Sorin Group receives CE Mark approval for Solo Smart stentless aortic valve

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that it has received CE Mark approval for the Solo Smart stentless aortic valve.

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

Pfizer-BioNTech and Sinovac vaccines boost SARS-CoV-2 neutralizing responses

Researchers in the United States and Chile have provided preliminary evidence that individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – mount a robust neutralizing antibody response against the virus that can be significantly boosted by two doses of Sinovac Biotech's CoronaVac vaccine or one dose of Pfizer-BioNTech's BNT162b2 vaccine.

Research journal to host a webinar on apoptotic signalling in normal and cancer cell biology

The business office of Science, the world's leading peer-reviewed research journal, is producing a webinar on "Apoptotic Signaling in Normal and Cancer Cell Biology" to be broadcast live online at 12 noon ET (4:00 GMT) September 22, 2009, sponsored by Promega.

Read more Medical News

› Verified 7 days ago